Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct;58(10):1539-1544.
doi: 10.2967/jnumed.116.181347. Epub 2017 Aug 10.

18F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?

Sally F Barrington  1 , Peter W M Johnson  2
Affiliations
Review

18F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?

Sally F Barrington et al. J Nucl Med. 2017 Oct.

Abstract

PET/CT using 18F-FDG is an essential part of the management of patients with lymphoma. Efforts to standardize PET acquisition and reporting, including the 5-point Deauville scale, have enabled PET to become a surrogate for treatment success or failure in common lymphoma subtypes. This review summarizes the key clinical-trial evidence that supports PET-directed personalized approaches in lymphoma. PET-guided therapy has improved outcomes in Hodgkin lymphoma, using less chemotherapy and more selective radiotherapy. Attempts to intensify chemotherapy in aggressive non-Hodgkin lymphomas have, however, proved ineffective in patients treated with rituximab and chemotherapy. Trials are under way to determine whether PET can obviate consolidation radiotherapy in patients with diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. More recently, PET has been reported to be a reliable predictor of outcome in follicular lymphoma requiring treatment, and prospective trials to test PET-guided therapy in this disease are anticipated.

Keywords: lymphoma; positron emission tomography; precision medicine.

PubMed Disclaimer

References

    1. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–3058. - PMC - PubMed
    1. Johnson PW. Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet? Hematology Am Soc Hematol Educ Program. 2016:316–322. - PMC - PubMed
    1. Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–354. - PMC - PubMed
    1. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–3068. - PMC - PubMed
    1. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372:1598–1607. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources